Feedback
What do they think of us?
We promote research by offering comprehensive support in the management and implementation of clinical studies.
We provide advice, solutions and structures that accompany the investigator throughout the clinical study process, from design to execution, guaranteeing compliance with all ethical and regulatory standards and ensuring the quality and validity of the research.
Our success lies in the combined efforts from the CRO and CTU teams that provide thorough support to the research team.
What do they think of us?
Check out some of the latest projects we’ve worked on.
The HOLA study evaluates the out-of-hospital administration of long-acting cabotegravir and rilpivirine as an optional therapy for HIV patients in Spain. It analyzes the acceptability, appropriateness, feasibility, and patient satisfaction with this community-based approach. It is the first study to administer HIV treatment in a community setting, aiming to enhance patient convenience and adherence.
ScienHub Research Support participated in the study’s design, coordination, and execution. It ensured proper training for healthcare professionals, supported patient recruitment, and monitored treatment outcomes. Its role was crucial in demonstrating the feasibility of this out-of-hospital therapy. It contributed to expanding treatment access and improving patient satisfaction in Spain.
The SUPERNOVA study is a phase I/III, randomized, double-blind clinical trial designed to assess the safety and neutralizing activity of the monoclonal antibodies AZD5156 and AZD3152 as pre-exposure prophylaxis for COVID-19 in individuals with immune deficiencies.
ScienHub’s Clinical Trials Unit (CTU) has led key aspects of this study, including the clinical protocol design, participant selection and recruitment, and real-time clinical data monitoring. Their work has ensured compliance with regulatory standards and the implementation of strict safety measures, reinforcing their commitment to biomedical research and the protection of vulnerable populations.
This phase II study, aimed at evaluating the efficacy of plitidepsin in patients with long COVID, included 90 participants.
ScienHub Research Support oversaw its execution, further strengthening its commitment to researching innovative treatments. Additionally, its involvement in this project highlighted its key role in advancing new therapies for this condition, reinforcing its presence in the field of medical research.